MA31466B1 - Derives de benzimidazole - Google Patents
Derives de benzimidazoleInfo
- Publication number
- MA31466B1 MA31466B1 MA32454A MA32454A MA31466B1 MA 31466 B1 MA31466 B1 MA 31466B1 MA 32454 A MA32454 A MA 32454A MA 32454 A MA32454 A MA 32454A MA 31466 B1 MA31466 B1 MA 31466B1
- Authority
- MA
- Morocco
- Prior art keywords
- benzimidazole derivatives
- mammals
- compounds
- treatment
- cell growth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne un composé de formule i (i) ou un de ses sels pharmaceutiquement acceptables, dans laquelle r1, r2, r3a, r3b, r4, r5, x, m et n sont tels que définis dans le présent document. De tels nouveaux dérivés de benzamidazole sont utiles dans le traitement de la croissance cellulaire anormale, telle que le cancer, chez les mammifères. L'invention concerne également un procédé d'utilisation de tels composés dans le traitement de la croissance cellulaire anormale chez les mammifères, notamment les humains, et des compositions pharmaceutiques qui contiennent de tels composés.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94728707P | 2007-06-29 | 2007-06-29 | |
US4164508P | 2008-04-02 | 2008-04-02 | |
PCT/IB2008/001575 WO2009004427A2 (fr) | 2007-06-29 | 2008-06-16 | Dérivés de benzamidazole |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31466B1 true MA31466B1 (fr) | 2010-06-01 |
Family
ID=40161351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32454A MA31466B1 (fr) | 2007-06-29 | 2009-12-29 | Derives de benzimidazole |
Country Status (46)
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2170860T5 (en) | 2007-06-29 | 2017-03-20 | Pfizer | benzimidazole |
ES2620027T3 (es) | 2008-09-03 | 2017-06-27 | Biomarin Pharmaceutical Inc. | Composiciones que incluyen derivados del ácido 6-aminohexanoico como inhibidores de HDAC |
JP2012529449A (ja) * | 2009-06-11 | 2012-11-22 | シエナ ビオテク ソシエタ ペル アチオニ | ヘッジホッグ経路アンタゴニストおよびそれらの治療的応用 |
US8907089B2 (en) | 2009-08-26 | 2014-12-09 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
ES2543151T3 (es) | 2010-10-20 | 2015-08-17 | Pfizer Inc | Derivados de 2-piridina como moduladores del receptor Smoothened |
JP5452459B2 (ja) | 2010-12-16 | 2014-03-26 | 株式会社Nttドコモ | ホーム基地局及びハンドオーバ方法 |
US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
CA3061239A1 (fr) | 2011-02-28 | 2012-09-07 | Biomarin Pharmaceutical Inc. | Inhibiteurs de l'histone deacetylase |
US9051305B2 (en) | 2011-03-08 | 2015-06-09 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
FR2980477B1 (fr) | 2011-09-23 | 2013-10-18 | Centre Nat Rech Scient | Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications |
CA2849820C (fr) * | 2011-09-26 | 2019-08-27 | Merck Patent Gmbh | Composes de benzylpiperidine utilises comme antagonistes des recepteurs a l'acide lysophosphatidique (lpa) |
IN2014DN11205A (fr) | 2012-06-20 | 2015-10-02 | Eutropics Pharmaceuticals Inc | |
WO2014081953A1 (fr) | 2012-11-21 | 2014-05-30 | Richard David J | Méthodes et compositions utiles dans le traitement de maladies faisant appel à des protéines de la famille bcl-2 et des dérivés d'isoquinoléine et de quinoléine |
CA2903490C (fr) | 2013-03-15 | 2021-04-13 | Biomarin Pharmaceutical Inc. | Inhibiteurs de hdac |
EP2996689A1 (fr) | 2013-04-17 | 2016-03-23 | Albert-Ludwigs-Universität Freiburg | Composés destinés à être utilisés comme inhibiteurs de bromodomaine |
US10732182B2 (en) | 2013-08-01 | 2020-08-04 | Eutropics Pharmaceuticals, Inc. | Method for predicting cancer sensitivity |
GB2519344A (en) * | 2013-10-18 | 2015-04-22 | Redx Pharma Ltd | Compounds |
US10640803B2 (en) | 2013-10-30 | 2020-05-05 | Eutropics Pharmaceuticals, Inc. | Methods for determining chemosensitivity and chemotoxicity |
EP3666768B1 (fr) * | 2015-04-24 | 2022-06-15 | Pfizer Inc. | Procédé de préparation d'une forme cristalline du 1-((2r,4r) -2-(1h-benzo [ d ] imidazol-2-yl ) -1-méthylpipéridin-4-yl) -3-(4-cyanophényl) urée maléate; le complexe (1:1) entre l'imidazole et le 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-méthylpipéridin-4-yl)-3-(4-cyanophényl)urée |
US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
JP2020164722A (ja) * | 2019-03-29 | 2020-10-08 | デクセリアルズ株式会社 | 接着剤組成物 |
EP4097093B8 (fr) | 2020-01-28 | 2024-02-28 | Assia Chemical Industries LTD | Procédés de préparation de glasdegib et de sel de celui-ci et formes à l'état solide de maléate de glasdegib et procédé de préparation associé |
CN113248475B (zh) * | 2020-02-11 | 2023-03-17 | 中国科学院上海药物研究所 | 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途 |
EP4126237B1 (fr) | 2020-03-26 | 2024-04-10 | LEK Pharmaceuticals d.d. | Forme dimaléate de 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-méthylpipéridine?-4-yl)-3-(4-cyanophényl)urée |
CN115997122A (zh) | 2020-06-26 | 2023-04-21 | 拉夸里亚创药株式会社 | 类维生素a与癌治疗剂的组合疗法有效的癌患者的选择方法、及类维生素a与癌治疗剂的组合药物 |
WO2023002362A1 (fr) | 2021-07-22 | 2023-01-26 | Pfizer Inc. | Traitement d'une malignité hématologique |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1638765A (zh) | 2001-07-27 | 2005-07-13 | 柯里斯公司 | Hedgehog信号转导途径介质、其相关组合物以及应用 |
AU2002358071B2 (en) | 2001-12-04 | 2008-06-12 | Actelion Pharmaceuticals Ltd | 4-(piperidyl- and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists |
TW200304820A (en) | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
AU2003301436A1 (en) * | 2002-10-17 | 2004-05-04 | Amgen Inc. | Benzimidazole derivatives and their use as vanilloid receptor ligands |
WO2005042495A1 (fr) | 2003-10-21 | 2005-05-12 | Imclone Systems Incorporated | Composes de (benzimidazol-2-yl)-phenyl-phenyl-uree et procedes d'inhibition de l'activite de l'heparanase |
US7309716B2 (en) | 2003-10-28 | 2007-12-18 | Vertex Pharmaceuticals Incorporated | Benzimidazoles useful as modulators of ion channels |
AU2005301962B2 (en) * | 2004-11-03 | 2011-10-20 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
DE102005012875B4 (de) | 2005-03-19 | 2006-11-16 | Sanofi-Aventis Deutschland Gmbh | Verwendung von Amino substituierten 8-N-Benzimidazolen |
WO2006124780A2 (fr) * | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibiteurs de la b-raf kinase |
WO2008064830A1 (fr) | 2006-11-27 | 2008-06-05 | Ucb Pharma, S.A. | Dérivés bicycliques et hétérobicycliques, leurs procédés de fabrication et leurs utilisations pharmaceutiques |
CA2672815A1 (fr) | 2006-12-15 | 2008-06-26 | Pfizer Products Inc. | Derives du benzamidazole |
DK2170860T5 (en) * | 2007-06-29 | 2017-03-20 | Pfizer | benzimidazole |
EP2303275A4 (fr) | 2008-06-17 | 2012-05-09 | Univ Duke | Modulateurs du récepteur smoothened |
EP2328871B1 (fr) | 2008-08-25 | 2020-04-01 | Novartis AG | Modulateurs de la voie hedgehog |
-
2008
- 2008-06-16 DK DK08762901.0T patent/DK2170860T5/en active
- 2008-06-16 BR BRPI0813412A patent/BRPI0813412B8/pt active IP Right Grant
- 2008-06-16 SI SI200831707A patent/SI2170860T1/sl unknown
- 2008-06-16 EA EA200971104A patent/EA016888B1/ru unknown
- 2008-06-16 CN CN200880022602XA patent/CN101687841B/zh active Active
- 2008-06-16 JP JP2010514162A patent/JP4567099B2/ja active Active
- 2008-06-16 GE GEAP200811622A patent/GEP20125702B/en unknown
- 2008-06-16 KR KR1020107001991A patent/KR101143246B1/ko active IP Right Grant
- 2008-06-16 WO PCT/IB2008/001575 patent/WO2009004427A2/fr active Application Filing
- 2008-06-16 MY MYPI20095266A patent/MY148636A/en unknown
- 2008-06-16 EP EP08762901.0A patent/EP2170860B9/fr active Active
- 2008-06-16 AP AP2009005089A patent/AP2377A/xx active
- 2008-06-16 AU AU2008272641A patent/AU2008272641B2/en active Active
- 2008-06-16 PL PL08762901T patent/PL2170860T3/pl unknown
- 2008-06-16 LT LTEP08762901.0T patent/LT2170860T/lt unknown
- 2008-06-16 RS RS20161132A patent/RS55395B9/sr unknown
- 2008-06-16 ES ES08762901.0T patent/ES2609258T3/es active Active
- 2008-06-16 CA CA2690953A patent/CA2690953C/fr active Active
- 2008-06-16 HU HUE08762901A patent/HUE030052T4/en unknown
- 2008-06-16 NZ NZ581889A patent/NZ581889A/en unknown
- 2008-06-16 PT PT87629010T patent/PT2170860T/pt unknown
- 2008-06-16 ME MEP-2009-349A patent/ME00962B/fr unknown
- 2008-06-19 US US12/142,119 patent/US8148401B2/en active Active
- 2008-06-19 PA PA20088785401A patent/PA8785401A1/es unknown
- 2008-06-20 UY UY31164A patent/UY31164A1/es active IP Right Grant
- 2008-06-25 HN HN2008000974A patent/HN2008000974A/es unknown
- 2008-06-27 PE PE2012000473A patent/PE20121010A1/es active IP Right Grant
- 2008-06-27 CL CL2008001922A patent/CL2008001922A1/es unknown
- 2008-06-27 AR ARP080102792A patent/AR067346A1/es active IP Right Grant
- 2008-06-27 PE PE2008001105A patent/PE20090772A1/es active IP Right Grant
- 2008-06-27 TW TW097124392A patent/TWI371451B/zh active
-
2009
- 2009-11-30 IL IL202420A patent/IL202420A/en active IP Right Grant
- 2009-12-07 CR CR11150A patent/CR11150A/es unknown
- 2009-12-08 DO DO2009000278A patent/DOP2009000278A/es unknown
- 2009-12-14 EC EC2009009803A patent/ECSP099803A/es unknown
- 2009-12-18 NI NI200900219A patent/NI200900219A/es unknown
- 2009-12-21 CU CU2009000225A patent/CU23847B1/es active IP Right Grant
- 2009-12-21 GT GT200900328A patent/GT200900328A/es unknown
- 2009-12-23 CO CO09147462A patent/CO6160232A2/es unknown
- 2009-12-25 TN TNP2009000544A patent/TN2009000544A1/fr unknown
- 2009-12-29 MA MA32454A patent/MA31466B1/fr unknown
-
2010
- 2010-06-09 HK HK10105659.9A patent/HK1139658A1/xx unknown
- 2010-08-04 JP JP2010175465A patent/JP2010280693A/ja active Pending
-
2012
- 2012-02-24 US US13/404,169 patent/US8431597B2/en active Active
-
2016
- 2016-11-23 HR HRP20161562TT patent/HRP20161562T2/hr unknown
- 2016-12-14 CY CY20161101293T patent/CY1118650T1/el unknown
-
2020
- 2020-07-15 NL NL301057C patent/NL301057I2/nl unknown
- 2020-08-11 NO NO2020027C patent/NO2020027I1/no unknown
- 2020-08-12 CY CY2020028C patent/CY2020028I2/el unknown
- 2020-08-13 HU HUS2000031C patent/HUS2000031I1/hu unknown
- 2020-08-20 FR FR20C1038C patent/FR20C1038I2/fr active Active
- 2020-08-26 LT LTPA2020528C patent/LTC2170860I2/lt unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31466B1 (fr) | Derives de benzimidazole | |
TN2009000428A1 (fr) | Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale | |
TNSN08270A1 (fr) | Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale | |
MA29926B1 (fr) | Derives de pyrazine | |
MA30403B1 (fr) | Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques | |
MA27389A1 (fr) | Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs. | |
TNSN07022A1 (fr) | Derives de pyridine | |
MA31419B1 (fr) | Derives de pyridine | |
MA30652B1 (fr) | Composes organiques | |
MA30821B1 (fr) | Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes | |
MA30352B1 (fr) | Pyridine [3,4-b] pyrazinones | |
TNSN06370A1 (fr) | Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale | |
DK1678166T3 (da) | Proteinkinaseinhibitorer | |
TN2014000115A1 (fr) | Derives de pyrrolopyrimidines et de purines | |
MA30781B1 (fr) | Inhibiteur de kinase | |
MA32009B1 (fr) | Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux | |
MA29909B1 (fr) | Derives de pyridazine | |
BR0313743A (pt) | Benzimidazol quinolinonas e usos destas | |
TW200607801A (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
MA31373B1 (fr) | Composes amino-heterocycliques | |
MA30411B1 (fr) | Derives de triazolopyrazine utiles comme agent anticancereux | |
MA33502B1 (fr) | Composés pyrazolopyrimidine inhibiteurs des jak et procédés | |
TW200738698A (en) | Organic compounds | |
MA32929B1 (fr) | Lactames en tant qu'inhibiteurs de bêta-sécrétase | |
TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. |